Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 4, 2007, Pages 338-340

  Soloway, Mark S ^a   Lee, Cheryl T ^b   Steinberg, Gary D ^c   Ghandi, Abdullah Al ^d   Jewett, Michael A S ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bladder cancer; High grade; Radical cystectomy; T1G3

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE;

ADJUVANT THERAPY; BLADDER CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CYSTECTOMY; HUMAN; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 34447105866     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.002     Document Type: Review

References (8)

1. Nieder A.M., and Soloway M.S. Eliminate the term "superficial" bladder cancer. J Urol 175 (2006) 417-418
2. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 6 Suppl 1 (2005) 108-125
3. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
4. Brake M., Loertzer H., Horsch R., et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163 (2000) 1697-1701
5. Herr H.W., Badalament R.A., Amato D.A., et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol 141 (1989) 22-29
6. Solsona E., Iborra I., Dumont R., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
7. Herr H.W. Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br J Urol 80 (1997) 762-765
8. Nieder A.M., Simon M.A., Kim S.S., et al. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in situ: Defining the risk of initial bladder preservation. Urology 67 (2006) 737-741